MBOT

SEC Filing Summary: StemCells, Inc. (Form 10-K)

Business Context and Reporting Period

Company: StemCells, Inc.
Reporting Period: Fiscal year ended December 31, 2006
Business Overview: StemCells, Inc. is a biopharmaceutical company focused on the discovery and development of cell-based therapeutics to treat damage to or degeneration of major organ systems, specifically the Central Nervous System (CNS), Liver, and Pancreas. The company utilizes tissue-derived stem and progenitor cells rather than embryonic stem cells.

Key Developments:

• Neural Program: The company is conducting a Phase I clinical trial for its lead product, HuCNS-SC (human neural stem cells), to treat infantile and late infantile neuronal ceroid lipofuscinosis (NCL/Batten disease). As of February 2007, two of six planned patients had been enrolled and transplanted.
• Liver Program: Preclinical development of human liver engrafting cells (hLEC) is ongoing, with a goal to initiate clinical trials within 12 months.
• Pancreas Program: Research stage identification of candidate pancreatic stem/progenitor cells.

Key Financial Metrics

Note: Revenue consists primarily of grants and licensing fees. The company has no product sales revenue.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 55% to $93,000 from $206,000 in 2005. This was driven by a significant drop in grant revenue (down 80% to $38,000) as prior year grants concluded, partially offset by a 183% increase in licensing revenue to $55,000.
• Increased Operating Expenses: Total operating expenses rose 29% to $21.5 million.
  • R&D Expenses: Increased 65% to $13.6 million, primarily due to expansion of cell processing and clinical development, including higher personnel costs and the adoption of SFAS 123R (stock-based compensation expensing).
  • Wind-down Expenses: Decreased 75% to $709,000 from $2.8 million, reflecting a reduction in the reserve for the former Rhode Island facility.
• Liquidity Improvement: Cash and cash equivalents increased by $17.3 million to $51.8 million, primarily due to a registered direct offering in April 2006 that raised approximately $33.4 million net of expenses.
• Other Income: Non-recurring income from the ReNeuron license agreement dropped significantly from $3.7 million in 2005 to $103,000 in 2006.

Guidance, Outlook, Risks, and Contingencies

Outlook and Guidance:

• The company does not expect to be profitable in the next several years and anticipates incurring additional operating losses.
• Management estimates existing capital resources may not be sufficient to fund operations beyond the next 18 months without additional financing.
• Future funding is expected to come from equity/debt offerings, grants, and collaborative arrangements.

Key Risks:

• Clinical Trial Dependency: The company's progress is heavily dependent on the success of its single Phase I clinical trial for NCL. Failure to enroll patients or demonstrate safety/efficacy could depress stock price and hinder capital raising.
• Liquidity Risk: Significant additional capital is required to sustain R&D, clinical trials, and regulatory pursuits. Failure to secure funding could force the company to delay programs or seek bankruptcy.
• Real Estate Obligations: The company remains obligated to lease and maintain former facilities in Rhode Island through 2013, incurring estimated net cash outlays of approximately $1.2 million annually, which diverts funds from R&D.
• Intellectual Property: Risks include the uncertainty of patent issuance, potential infringement claims, and the need to license third-party technology.

Unusual Items:

• ReNeuron Transaction: In 2005, the company received equity in ReNeuron Group plc as part of a license agreement. In 2006, the company recorded $103,000 in income related to anti-dilution shares. In February 2007 (subsequent event), the company sold approximately 5.3 million ReNeuron shares for net proceeds of $3.1 million.
• Stock-Based Compensation: Adoption of SFAS 123R in 2006 resulted in the recognition of approximately $2.3 million in stock-based compensation expense, increasing the reported net loss.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $51.8 million cash balance against the stated 18-month runway and current burn rate.
• Clinical Trial Progress: Monitor enrollment rates and safety data for the Phase I NCL trial (HuCNS-SC).
• Rhode Island Liability: Track the company's ability to sublease or divest the Rhode Island facilities to reduce the $6.75 million accrued wind-down liability.
• Financing Needs: Assess the terms and timing of any future equity or debt offerings required to fund operations.
• Patent Portfolio: Review the status of pending patent applications and any ongoing litigation (e.g., suit against Neuralstem, Inc.).